БРИСТОЛЬ-МЕЙЕРЗ СКВИББ КОМПАНИ (US);ПФАЙЗЕР ИНК. (US)
发明人:
БЕНДЕР Стивен Ли (US),КАСПЕРСОН Джеральд Фрайес (US),ХУ-ЛОУ Дана Дан (US),ЦЗЯН Синь (US),ЛИ Ган (US),НОРТ Майкл Айдан (US),ВАН Цзяньин (US),УИКМАН Грант (GB),БРАМС Петер (US),ХУАН Хайчунь (US),ДЕВО Бр
申请号：
RU2010136940/10
公开号：
RU2010136940A
申请日:
2009.02.04
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. Isolated full-length human IgG1 antibody having at least one amino acid mutation in the Fc region, which has a higher antibody-dependent cell cytotoxicity (ADCC) than an identical antibody without at least one amino acid mutation in Fc -regions, and capable of binding to human integrin α5β1 with KD 1 · 10-7 or less. ! 2. The antibody according to claim 1, where the specified antibody binds to integrin α5β1 person with KD 5 · 10-8 or less. ! 3. The selected monoclonal antibody or antigen binding site thereof that binds to human integrin α5β1 with KD 1 · 10-7 or less and contains a variable region of the heavy chain that is at least 90% identical to the amino acid sequence shown in SEQ ID NO : 7. ! 4. The antibody or antigen binding site according to claim 3, further comprising a variable region of the light chain that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 8. ! 5. An isolated monoclonal antibody or antigen binding site thereof comprising:! (a) the variable region of the heavy chain CDR1 containing SEQ ID NO: 1； ! (b) the variable region of the heavy chain CDR2 containing SEQ ID NO: 2； ! (c) the variable region of the heavy chain CDR3 containing SEQ ID NO: 3； ! (d) the variable region of the light chain CDR1 containing SEQ ID NO: 4； ! (e) the variable region of the light chain CDR2 containing SEQ ID NO: 5； and! (f) the variable region of the light chain CDR3 containing SEQ ID NO: 6. ! 6. The antibody or its antigennegative plot according to claim 5, containing:! (a) the variable region of the heavy chain containing the amino acid sequence of SEQ ID NO: 7； and! (b) the variable region of the light chain containing amino acid1. Выделенное полноразмерное IgG1-антитело человека, имеющее, по меньшей мере, одну мутацию аминокислот в Fc-области, у которого наблюдается более высокая антителозависимая клеточная цитотоксичность (ADCC), чем у идентичного антитела без, по меньшей мере, одной мутации аминокислот в Fc-области, и способное связыв
